Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Summary
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Official title: A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-01-26
Completion Date
2028-07-14
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
JNJ-90301900
JNJ-90301900 will administered via intratumoral and/or intranodal injection.
Cisplatin
Cisplatin will be administered intravenously.
Intensity Modulated Radiation Therapy (IMRT)
IMRT radiation therapy will be administered.
Locations (11)
City of Hope
Duarte, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Moffit Cancer center
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Montefiore Medical Center
The Bronx, New York, United States
Hopital De La Cavale Blanche
Brest, France
Hopital La Timone
Marseille, France
Centre Henri Becquerel
Rouen, France
Gustave Roussy
Villejuif, France
Aichi Cancer Center
Nagoya, Japan
Tokyo Medical University Hospital
Tokyo, Japan